Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-
5 hours ago
- #clinical trial
- #androgen receptor inhibitor
- #prostate cancer
- Deutenzalutamide, a novel androgen receptor inhibitor, shows promise for metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel and abiraterone.
- In the phase III HC-1119-04 trial involving 417 patients, deutenzalutamide significantly improved radiographic progression-free survival (rPFS) with a hazard ratio of 0.58, reducing progression risk by 42%.
- Initial overall survival (OS) analysis was not significant, but sensitivity analyses adjusting for subsequent therapies indicated significant OS benefits with hazard ratios ranging from 0.65 to 0.73.
- The safety profile was favorable, with grade 3 or higher treatment-related adverse events occurring in 22.3% of deutenzalutamide patients versus 15.0% with placebo, and no seizures or falls reported.
- These results support deutenzalutamide as a new treatment option for mCRPC, offering enhanced pharmacokinetics and potential efficacy over existing therapies.